Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00606346 · ClinicalTrials.gov registry record
A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease
A clinical trial of Ulcerative Colitis and Crohn's Disease, sponsored by Janssen Biotech.
- Active
- Registry status
- 4,970
- Enrollment target
- 20
- Study locations
NCT00606346: Active study of Ulcerative Colitis and Crohn's Disease, sponsored by Janssen Biotech.
NCT00606346 is a study of Ulcerative Colitis and Crohn's Disease that is active but no longer recruiting, run by Janssen Biotech. The registered enrollment target is 4,970 participants, above the 2,017-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (146% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00606346, a study of Ulcerative Colitis and Crohn's Disease, is active but no longer recruiting, sponsored by Janssen Biotech.
- ACTIVE NOT RECRUITING
- Registry status
- 4,970 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the long-term safety and clinical status of pediatric patients with Inflammatory Bowel Disease (IBD). Particular attention will be directed to recording safety outcomes reported in association with infliximab and other prescribed IBD therapies. In addition, information on disease status and quality of life will be collected.
Primary Outcome
The objective of this registry is to obtain long-term safety and clinical status information on pediatric patients with IBD (ie, CD, UC, or IC).
Conditions Studied
Interventions
- BIOLOGICAL Anti TNF therapy including infliximab
- DRUG No Biologics
Study Locations (20)
California
- - Los Angeles
- - Oakland
- - Sacramento
- - San Diego
- - San Francisco
Florida
- - Gainesville
- - Miami
- - Orlando
Connecticut
- - Hartford
- - New Haven
Alabama
- - Mobile
Arizona
- - Phoenix
Colorado
- - Aurora
Georgia
- - Atlanta
Idaho
- - Boise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,970 participants |
| Start Date | 2007-05-31 |
| Est. Completion | 2038-06-30 |
What the registry record for NCT00606346 still lists
NCT00606346 is an observational study that tracks outcomes without assigning an intervention. Its 4,970 participants enrollment target places it among the larger protocols in the corpus, above the 2,017-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (146% higher).
The record links to 4 conditions, with Ulcerative Colitis appearing as the primary indexed condition, and to 2 interventions - of which Anti TNF therapy including infliximab is the first listed.
NCT00606346 names 20 study sites across 13 states, led by California, Florida, Connecticut.
Frequently Asked Questions
What is clinical trial NCT00606346 about?
NCT00606346 is a clinical study titled "A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease". The purpose of this study is to evaluate the long-term safety and clinical status of pediatric patients with Inflammatory Bowel Disease (IBD). Particular attention will be directed to recording safety outcomes reported in association with infliximab and other prescribed IBD therapies. In addition, i...
What is the current status of trial NCT00606346?
This trial is currently active not recruiting. The enrollment target is 4,970 participants. The study started on 2007-05-31. Estimated completion is 2038-06-30.
What conditions does trial NCT00606346 study?
This clinical trial studies the following conditions: Ulcerative Colitis, Crohn's Disease, Inflammatory Bowel Diseases, Indeterminate Colitis.
What interventions are being tested in trial NCT00606346?
The interventions under investigation include: Anti TNF therapy including infliximab (BIOLOGICAL), No Biologics (DRUG).
Who is sponsoring clinical trial NCT00606346?
This trial is sponsored by Janssen Biotech, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00606346 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00606346's enrollment target sits among peer trials
4,970 3rd of 122 higher than 120 of 122 other Ulcerative Colitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ulcerative Colitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
RECRUITING · Phase 2
-
Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention
RECRUITING
-
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
RECRUITING · NA
-
A Study of Endoscopic Sleeve Gastroplasty for Obesity in Ulcerative Colitis
RECRUITING · NA
-
Registry and Biorepository for IBD in Central Texas
RECRUITING
-
Nicotinamide Riboside in Ulcerative Colitis
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00060541 · 5,000 participants
Evaluation and Treatment of Neurosurgical Disorders
- NCT00575081 · 5,000 participants
Physiological Brain Atlas Development
- NCT00736749 · 5,000 participants
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
- NCT00900198 · 5,000 participants
Collection of Tissue Samples for Cancer Research
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI